瑞银：给予再鼎医药“买入”评级 目标价33.5港元

Core Viewpoint - UBS initiates coverage on Zai Lab with a "Buy" rating and a target price of HKD 33.5, highlighting the company's growth potential in the biopharmaceutical sector [1] Company Overview - Zai Lab has developed into a biopharmaceutical company with eight commercialized products, covering areas such as oncology, immunology, neuroscience, and infectious diseases [1] Product Pipeline - UBS expects the core product VYVGART to continue expanding its indications and increasing sales [1] - Several key candidate drugs are anticipated to receive approval, contributing to future growth [1] - The business development opportunities for ZL-1310 (DLL3ADC) and ZL-1503 (IL-13/IL-31R) are viewed as recent growth drivers [1]